Trial Profile

Chemotherapy-Free pCR-Guided Strategy With Subcutaneous Trastuzumab-pertuzumab and T-DM1 in HER2-positive Early Breast Cancer (PHERGAIN-2)

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 10 Jul 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pertuzumab/trastuzumab (Primary) ; Trastuzumab emtansine (Primary) ; Gonadotropin releasing hormone stimulants; Letrozole; Tamoxifen
Indications Carcinoma; Early breast cancer; HER2 positive breast cancer; Male breast cancer
Focus Adverse reactions; Therapeutic Use
Acronyms PHERGAIN-2

Most Recent Events

07 May 2026 Results published in the Media Release
07 May 2026 According to a MEDSIR media release, the results of the PHERGain and PHERGain-2 studies were presented at the ESMO Breast 2026 scientific congress.
20 Nov 2025 Planned primary completion date changed from 1 Sep 2025 to 1 Mar 2027.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com